Here’s Why We’re Linking Claims with Our EHR Data
Every case of cancer tells us a story that can’t be captured on an intake form. At Flatiron Health, we’re helping researchers piece those stories together to unlock breakthroughs in...
Tag: Flatiron Health
Ovation Appoints Marty Miller as Chief Revenue Officer and Hana Dembe as Head of Product Marketing
The additions strengthen Ovation’s commercial team to focus on accelerating growth in genomic data business November 10, 2022 09:15 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Clinicogenomic data and lab software...
Flatiron Health Announces Research to be Presented at International Society for Pharmacoeconomics and Outcomes Research Europe 2022 Annual Meeting
November 04, 2022 09:30 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Flatiron Health is pleased to announce their attendance and presence at the ISPOR, The Professional Society for Health Economics and Outcomes...
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia
PURPOSE Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain. Within a pragmatic, randomized trial of a...
Flatiron Health Expands Leadership Team with Two New Executive Hires
Appoints Bruce Gottlieb as Chief Operating Officer and Ara Tucker as Chief People Officer October 11, 2022 09:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Flatiron HealthⓇ is pleased to announce today...
Mutations of SPOP (mtSPOP) as Treatment Selection Biomarkers
Oct 5, 2022 For patients with mCSPC, the current standard of treatment is to intensify androgen deprivation therapy (ADT) with docetaxel or androgen receptor axis-targeted therapy (ARAT: abiraterone, apalutamide, enzalutamide)....
Connect patient genomics with clinical outcomes
Conduct disease-specific and disease-agnostic analyses Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses. Patient data across...
Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available
Partnership broadens precision medicine access at the point of care with seamless ordering and receipt of Caris molecular profiling results directly in patient records via the OncoEMR® platform IRVING, Texas, Sept....
Integrated evidence: How patient data derived from digital healthcare delivery can drive innovation
For a long time, doctors’ offices, large or small, operated under a seeming contradiction; even as modern medicine pushed the frontiers of innovation, providing new treatments and sometimes cures for...
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer
The ongoing real-world Prospective Clinicogenomic (PCG) Study compares the clinical actionability of both tissue- and blood-based comprehensive genomic profiling to limited tissue testing in this patient population August 08, 2022...